Johnson & Johnson stands alone as a leader across major healthcare industries. It maintains a diverse revenue base, a developing research pipeline, and exceptional cash flow generation that together create a Morningstar Economic Moat Rating of wide.
J&J's strong position in oncology (Darzalex and Carvykti) and next-generation immunology product Tremfya (following Stelara) create a foundation of innovative drugs.
J&J's late-stage drug pipeline could face significant competitive threats, as oncology and immunology remain popular areas for biopharma investment.
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Price/Earnings (Normalized) | 23.82 | 13.57 | 44.80 |
Price/Book Value | 7.33 | 6.45 | 8.47 |
Price/Sales | 6.44 | 4.80 | 5.36 |
Price/Cash Flow | 22.07 | 14.16 | 16.10 |
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Quick Ratio | 0.73 | 0.55 | 0.71 |
Current Ratio | 1.09 | 0.86 | 1.32 |
Interest Coverage | 25.00 | 11.90 | 4.28 |
|
Metric
|
JNJ
|
NVS
|
MRK
|
|---|---|---|---|
Return on Assets (Normalized) | 13.42% | 14.74% | 6.27% |
Return on Equity (Normalized) | 32.69% | 39.06% | 16.68% |
Return on Invested Capital (Normalized) | 20.33% | 21.25% | 9.82% |
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Eli Lilly and Co
LLY
| LOCK|>#p?^%D | LOCK|B?& | $1T | |||
| AbbVie Inc
ABBV
| LOCK|CKtGYR | LOCK|!zs | $464B | |||
| Merck & Co Inc
MRK
| LOCK|N&@<>y | LOCK|L!^ | $356B | |||
| Roche Holding AG ADR
RHHBY
| LOCK|?@<#P<Y | LOCK|tF? | $333B | |||
| Novartis AG ADR
NVS
| LOCK|P#&^Q@F | LOCK|^n | $266B | |||
| AstraZeneca PLC
AZN
| LOCK|vwnFlq% | LOCK|vv^ | $248B | |||
| Amgen Inc
AMGN
| LOCK|J#<qbHZ | LOCK|^w | $218B | |||
| Gilead Sciences Inc
GILD
| LOCK|TsQ%LnC | LOCK|#@B | $179B | |||
| Novo Nordisk AS ADR
NVO
| LOCK|!xSfjcV | LOCK|FqD | $165B |
United States